Immune Checkpoints PVR and PVRL2 Are Prognostic Markers in AML and Their Blockade Represents a New Therapeutic Option

Oncogene - United Kingdom
doi 10.1038/s41388-018-0288-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Concordance of Immune Checkpoints Within Tumor Immune Contexture and Their Prognostic Significance in Gastric Cancer

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

The Blockade of Immune Checkpoints in Cancer Immunotherapy

Nature Reviews Cancer
Cancer ResearchOncology
2012English

New Therapeutic Targets for Cancer: The Interplay Between Immune and Metabolic Checkpoints and Gut Microbiota

Clinical and Translational Medicine
MedicineMolecular Medicine
2019English

The Interaction of TIGIT With PVR and PVRL2 Inhibits Human NK Cell Cytotoxicity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

PD-1 and Its Ligands Are Important Immune Checkpoints in Cancer

Oncotarget
Oncology
2016English

Immune Checkpoints in MSI and CSI Colorectal Cancers and Their Translational Implications

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

T Cells in Chronic Lymphocytic Leukemia Display Dysregulated Expression of Immune Checkpoints and Activation Markers

Haematologica
Hematology
2016English

Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications

Frontiers in Oncology
Cancer ResearchOncology
2019English

Immune Checkpoints in Thymic Epithelial Tumors: Challenges and Opportunities

Immuno-Oncology Technology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy